Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography: a feasibility study

Jonathan Weir-McCall (Lead / Corresponding author), Richard D. White, Prasad G. Ramkumar, Stephen J. Gandy, Faisel Khan, Jill J. F. Belch, Allan D. Struthers, J. Graeme Houston

Research output: Contribution to journalArticle

1 Citation (Scopus)
70 Downloads (Pure)

Abstract

Assess the feasibility of whole body magnetic resonance angiography (WB-MRA) for monitoring global atheroma burden in a population with peripheral arterial disease (PAD). 50 consecutive patients with symptomatic PAD referred for clinically indicated MRA were recruited. Whole body MRA (WB-MRA) was performed at baseline, 6 months and 3 years. The vasculature was split into 31 anatomical arterial segments. Each segment was scored according to degree of luminal narrowing: 0 = normal, 1 = <50 %, 2 = 50–70 %, 3 = 71–99 %, 4 = vessel occlusion. The score from all assessable segments was summed, and then normalised to the number of assessable vessels. This normalised score was divided by four (the maximum vessel score) and multiplied by 100 to give a final standardised atheroma score (SAS) with a score of 0–100. Progression was assessed with repeat measure ANOVA. 36 patients were scanned at 0 and 6 months, with 26 patients scanned at the 3 years follow up. Only those who completed all three visits were included in the final analysis. Baseline atherosclerotic burden was high with a mean SAS of 15.7 ± 10.3. No significant progression was present at 6 months (mean SAS 16.4 ± 10.5, p = 0.67), however there was significant disease progression at 3 years (mean SAS 17.7 ± 11.5, p = 0.01). Those with atheroma progression at follow-up were less likely to be on statin therapy (79 vs 100 %, p = 0.04), and had significantly higher baseline SAS (17.6 ± 11.2 vs 10.7 ± 5.1, p = 0.043). Follow up of atheroma burden is possible with WB-MRA, which can successfully quantify and monitor atherosclerosis progression at 3 years follow-up.

Original languageEnglish
Pages (from-to)825-832
Number of pages8
JournalInternational Journal of Cardiovascular Imaging
Volume32
Issue number5
Early online date25 Jan 2016
DOIs
Publication statusPublished - May 2016

Fingerprint

Feasibility Studies
Atherosclerotic Plaques
Angiography
Magnetic Resonance Angiography
Peripheral Arterial Disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Disease Progression
Atherosclerosis
Analysis of Variance
Population

Keywords

  • Atherosclerosis
  • Disease progression
  • Magnetic resonance angiography
  • Peripheral arterial disease
  • Whole-body imaging

Cite this

@article{1636cb1cec5e4e49b9061aa218d7ea79,
title = "Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography: a feasibility study",
abstract = "Assess the feasibility of whole body magnetic resonance angiography (WB-MRA) for monitoring global atheroma burden in a population with peripheral arterial disease (PAD). 50 consecutive patients with symptomatic PAD referred for clinically indicated MRA were recruited. Whole body MRA (WB-MRA) was performed at baseline, 6 months and 3 years. The vasculature was split into 31 anatomical arterial segments. Each segment was scored according to degree of luminal narrowing: 0 = normal, 1 = <50 {\%}, 2 = 50–70 {\%}, 3 = 71–99 {\%}, 4 = vessel occlusion. The score from all assessable segments was summed, and then normalised to the number of assessable vessels. This normalised score was divided by four (the maximum vessel score) and multiplied by 100 to give a final standardised atheroma score (SAS) with a score of 0–100. Progression was assessed with repeat measure ANOVA. 36 patients were scanned at 0 and 6 months, with 26 patients scanned at the 3 years follow up. Only those who completed all three visits were included in the final analysis. Baseline atherosclerotic burden was high with a mean SAS of 15.7 ± 10.3. No significant progression was present at 6 months (mean SAS 16.4 ± 10.5, p = 0.67), however there was significant disease progression at 3 years (mean SAS 17.7 ± 11.5, p = 0.01). Those with atheroma progression at follow-up were less likely to be on statin therapy (79 vs 100 {\%}, p = 0.04), and had significantly higher baseline SAS (17.6 ± 11.2 vs 10.7 ± 5.1, p = 0.043). Follow up of atheroma burden is possible with WB-MRA, which can successfully quantify and monitor atherosclerosis progression at 3 years follow-up.",
keywords = "Atherosclerosis, Disease progression, Magnetic resonance angiography, Peripheral arterial disease, Whole-body imaging",
author = "Jonathan Weir-McCall and White, {Richard D.} and Ramkumar, {Prasad G.} and Gandy, {Stephen J.} and Faisel Khan and Belch, {Jill J. F.} and Struthers, {Allan D.} and Houston, {J. Graeme}",
year = "2016",
month = "5",
doi = "10.1007/s10554-016-0842-z",
language = "English",
volume = "32",
pages = "825--832",
journal = "International Journal of Cardiovascular Imaging",
issn = "1569-5794",
publisher = "Springer Verlag",
number = "5",

}

Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography : a feasibility study. / Weir-McCall, Jonathan (Lead / Corresponding author); White, Richard D.; Ramkumar, Prasad G.; Gandy, Stephen J.; Khan, Faisel; Belch, Jill J. F.; Struthers, Allan D.; Houston, J. Graeme.

In: International Journal of Cardiovascular Imaging, Vol. 32, No. 5, 05.2016, p. 825-832.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography

T2 - a feasibility study

AU - Weir-McCall, Jonathan

AU - White, Richard D.

AU - Ramkumar, Prasad G.

AU - Gandy, Stephen J.

AU - Khan, Faisel

AU - Belch, Jill J. F.

AU - Struthers, Allan D.

AU - Houston, J. Graeme

PY - 2016/5

Y1 - 2016/5

N2 - Assess the feasibility of whole body magnetic resonance angiography (WB-MRA) for monitoring global atheroma burden in a population with peripheral arterial disease (PAD). 50 consecutive patients with symptomatic PAD referred for clinically indicated MRA were recruited. Whole body MRA (WB-MRA) was performed at baseline, 6 months and 3 years. The vasculature was split into 31 anatomical arterial segments. Each segment was scored according to degree of luminal narrowing: 0 = normal, 1 = <50 %, 2 = 50–70 %, 3 = 71–99 %, 4 = vessel occlusion. The score from all assessable segments was summed, and then normalised to the number of assessable vessels. This normalised score was divided by four (the maximum vessel score) and multiplied by 100 to give a final standardised atheroma score (SAS) with a score of 0–100. Progression was assessed with repeat measure ANOVA. 36 patients were scanned at 0 and 6 months, with 26 patients scanned at the 3 years follow up. Only those who completed all three visits were included in the final analysis. Baseline atherosclerotic burden was high with a mean SAS of 15.7 ± 10.3. No significant progression was present at 6 months (mean SAS 16.4 ± 10.5, p = 0.67), however there was significant disease progression at 3 years (mean SAS 17.7 ± 11.5, p = 0.01). Those with atheroma progression at follow-up were less likely to be on statin therapy (79 vs 100 %, p = 0.04), and had significantly higher baseline SAS (17.6 ± 11.2 vs 10.7 ± 5.1, p = 0.043). Follow up of atheroma burden is possible with WB-MRA, which can successfully quantify and monitor atherosclerosis progression at 3 years follow-up.

AB - Assess the feasibility of whole body magnetic resonance angiography (WB-MRA) for monitoring global atheroma burden in a population with peripheral arterial disease (PAD). 50 consecutive patients with symptomatic PAD referred for clinically indicated MRA were recruited. Whole body MRA (WB-MRA) was performed at baseline, 6 months and 3 years. The vasculature was split into 31 anatomical arterial segments. Each segment was scored according to degree of luminal narrowing: 0 = normal, 1 = <50 %, 2 = 50–70 %, 3 = 71–99 %, 4 = vessel occlusion. The score from all assessable segments was summed, and then normalised to the number of assessable vessels. This normalised score was divided by four (the maximum vessel score) and multiplied by 100 to give a final standardised atheroma score (SAS) with a score of 0–100. Progression was assessed with repeat measure ANOVA. 36 patients were scanned at 0 and 6 months, with 26 patients scanned at the 3 years follow up. Only those who completed all three visits were included in the final analysis. Baseline atherosclerotic burden was high with a mean SAS of 15.7 ± 10.3. No significant progression was present at 6 months (mean SAS 16.4 ± 10.5, p = 0.67), however there was significant disease progression at 3 years (mean SAS 17.7 ± 11.5, p = 0.01). Those with atheroma progression at follow-up were less likely to be on statin therapy (79 vs 100 %, p = 0.04), and had significantly higher baseline SAS (17.6 ± 11.2 vs 10.7 ± 5.1, p = 0.043). Follow up of atheroma burden is possible with WB-MRA, which can successfully quantify and monitor atherosclerosis progression at 3 years follow-up.

KW - Atherosclerosis

KW - Disease progression

KW - Magnetic resonance angiography

KW - Peripheral arterial disease

KW - Whole-body imaging

UR - http://www.scopus.com/inward/record.url?scp=84955497124&partnerID=8YFLogxK

U2 - 10.1007/s10554-016-0842-z

DO - 10.1007/s10554-016-0842-z

M3 - Article

C2 - 26809611

AN - SCOPUS:84955497124

VL - 32

SP - 825

EP - 832

JO - International Journal of Cardiovascular Imaging

JF - International Journal of Cardiovascular Imaging

SN - 1569-5794

IS - 5

ER -